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Abstract
Objective—To assess and compare the benefits of three psychosocial treatments for rheumatoid
arthritis.
Methods—Rheumatoid arthritis (RA) patients were randomized to cognitive-behavior therapy
(CBT), relaxation response training (RR), or arthritis education (AE). All treatment was conducted
in groups. Follow-up occurred immediately after treatment and 6 and 12 months later. Pain, other
RA symptoms, role impairment, and psychological distress were assessed with standardized self-
report questionnaires. Arthritis severity and activity were assessed with a joint examination,
erythrocyte sedimentation rate, grip strength, and walking time. An intent-to-treat analytic strategy
was employed. Linear regression was used to establish treatment effect on pain and other RA
symptoms, while adjusting for sociodemographic and clinical variables.
Results—168 patients were randomized. Pain improved significantly at 12 months in the RR and
AE groups and showed a non-significant positive trend with CBT. Other RA symptoms improved
significantly with CBT and AE, and showed a non-significant trend with RR. There were no
significant differences in the outcomes across the 3 treatment groups. When the results for all 3
groups were aggregated, significant benefits were found for pain, other RA symptoms, self-care
activities and social activities. Effect sizes ranged between 0.26 and 0.35.
Conclusions—These three psychosocial treatments were beneficial, with treatment effect sizes
in the small to moderate range. The effects appeared immediately after treatment and were
generally sustained at long-term follow-up. These benefits were achieved over and above those
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resulting from medical management. These treatments constitute an effective augmentation to
standard medical therapy for rheumatoid arthritis patients.
INTRODUCTION
Despite major advances in the medical management of rheumatoid arthritis (RA), it remains
a chronic, painful and disabling condition. RA symptoms guide treatment, prompt physician
visits, and affect patients’ quality of life and productivity. However, patients with
comparable disease severity differ widely in their symptoms and psychological factors
partially explain this inter-individual variability in symptoms. 1–6. The statistical correlation
between pain and objective measures of disease severity is modest, ranging between 0.23
and 0.52 7, and successful treatment of the disease process is not necessarily accompanied
by improvement in symptoms 8. RA symptoms result from the interplay of soma and
psyche, and thus psychological factors contribute to symptoms and disability. This suggests
a role for psychosocial treatments in the long-term management of arthritis symptoms 9.
The literature on psychosocial and psychoeducational treatments as adjuncts to medical
therapy indicates that they reduce RA symptoms, disability, and role impairment, and
improve coping. Most of these therapies consist of varying combinations of three basic
elements: (1) Education, encompassing information and explanation about the disease, its
symptoms and its treatment, joint protection, pacing of activities, use of heat and cold, and
graduated exercise; (2) Stress reduction programs incorporating relaxation response training,
progressive muscle relaxation, mindfulness meditation, and biofeedback; (3) Cognitive/
behavior therapy to enhance coping skills with techniques such as altering pain-related
cognitions, attention refocusing and distraction, goal-setting and self-reinforcement, and
pain coping strategies. Several meta-analyses indicate that these interventions are effective,
but their comparability and durability remain unclear 10–12.
The current study was designed as a randomized, controlled, intervention trial of the long-
term benefits of these three psychosocial treatments for rheumatoid arthritis: cognitive/
behavior therapy, relaxation response training, and a patient education program. We
assessed and compared their effects on symptoms, disability and role impairment. We
hypothesized that the patients undergoing both the cognitive behavior therapy and the
relaxation response would have significantly fewer symptoms and less role impairment than
those undergoing the arthritis education program.
METHODS
Study Design
Eligible subjects completed a baseline interview and were then randomized to one of three
treatment conditions: Cognitive-behavior therapy (CBT), relaxation response training (RR),
or arthritis education (AE), the latter designed to serve as an ethically justifiable attention
control condition. To avoid biasing the subjects, none of the three treatment modalities was
ever specifically identified as the control treatment. All treatment was conducted in groups
of 5–8 patients, over an 8–12 week period, followed by monthly booster telephone calls.
Outcomes were assessed with in-person interviews immediately following treatment, and 6
and 12 months later. Data were gathered by research assistants blind to treatment modality,
and the therapists had no role in data collection. The primary outcome was the change in RA
symptoms between the baseline and 12 month assessments. The protocol was approved by
the Partners Human Research Committee and all subjects provided written informed
consent.
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Patients were enrolled between June, 2002 and September, 2005. Long-term follow-up was
completed in October, 2006. The baseline battery included self-report questionnaires, a grip
strength test and a walking time test, followed by a standardized joint examination and the
collection of a blood sample. Once five subjects were accrued, this group was randomly
assigned by computer to one of the three treatment modalities. However, after accruing 127
patients, unequal numbers of patients across the treatment arms led us to an unbalanced
randomization for the remaining 41 patients in order to restore balance.
Subjects and Setting
Most subjects were identified through the hospital’s computerized patient registry, which
was queried for all patients with a diagnosis of RA who had had a visit within the previous
year. A smaller number of subjects volunteered for the study in response to public
announcements and advertisements.
Patients who were between 20 and 75 years old, met ACR criteria for rheumatoid arthritis,
and were fluent and literate in English were eligible. There were three exclusion criteria:
fibromyalgia; serious medical comorbidity likely to progress substantially or cause death in
the ensuing 12 months; and currently receiving psychosocial treatment for RA.
Treatment Conditions
The CBT consisted of 12, tightly manualized, 60–75 minute sessions. It was a slightly
modified and shortened version of the treatment program of Bradley 13–15 to help patients
develop effective coping strategies, enhance self-efficacy and personal control, and modify
maladaptive behaviors that maintain symptoms and disability. Techniques taught included
problem solving and goal setting, relabeling and reframing of symptoms, enhanced
awareness of pain behaviors, activity pacing, and distraction and attention refocusing.
Homework was given at the end of each session and reviewed at the beginning of the
following session.
The RR consisted of 8, 50–60 minute sessions. Relaxation training has been used to reduce
the pain associated with a variety of medical conditions 16,17. Recent work has begun to
illuminate possible changes in gene expression resulting from relaxation training that may
relate to long-term physiological effects 18. The RR in this study included the following
topics: the relaxation response – psycho-physiological and cognitive aspects; diaphragmatic
breathing; progressive muscle relaxation (PMR); and generalization of relaxation response
skills to symptom management. The protocol was tightly manualized, standardized, and
largely, based upon the Jacobsenian technique 19,20. Patients were given audiotapes that
included the full PMR technique, were assigned daily practice, and were instructed to record
their activities, which were reviewed in subsequent treatment sessions.
Patients in the AE group received 8, 50 minute, scripted talks and printed material about RA
and its treatment. The sessions were didactic in tone, no specific recommendations about
behavioral or attitudinal change were made, no skills training was provided, and no active,
problem-solving was included. Topics covered included RA pathophysiology; arthritis
medication and therapies; physical exercise and activity; nutrition and diet; and the nature of
stress. Group support was not specifically encouraged, but did occur spontaneously.
For all three treatments, brief booster phone calls occurred 2 and 4 weeks following the final
sessions and then 2, 3, 6, 9 and 12 months later. These calls focused on review of
information learned previously and consolidation of skills, maintenance of gains, problem
solving, and relapse prevention. Each therapist each administered all three treatments.
Barsky et al. Page 3













Therapists had master’s or doctoral degrees and prior training and experience conducting
cognitive/behavior therapy and relaxation response training. They underwent regular,
ongoing supervision throughout the study. Treatment fidelity was established with blind
ratings of randomly selected audio- taped treatment sessions and was found to be high.
Assessment
Rheumatoid Arthritis Pain and Other Symptoms—Pain and symptoms were the
primary outcome measures. The Rheumatoid Arthritis Symptom Questionnaire (RASQ) is a
14-item, face-valid, self-report questionnaire. It includes pain (2 items), stiffness, swelling,
restriction of movement, fatigue, poor appetite, difficulty sleeping and malaise. These are
rated on a 10 cm visual analog scale from “no” distress to the “worst possible” distress.
Visual analog self-rating is the most widely employed method for measuring pain and other
symptoms and this method has been shown to be reliable and content valid 10,21–23
Role Impairment and Disability—The Arthritis Impact Measurement Scale (AIMS-2) is
a widely used self-report measure of several domains of functioning with rheumatic disease,
including mobility, walking and bending, self-care tasks, household tasks, social activities,
and work 24–26. It is valid and sensitive to change and has excellent internal consistency and
reliability 24,26,27.
Disease Severity and Disease Activity—There is no generally agreed upon standard
for assessing RA disease activity and severity, and various indices including laboratory
parameters, physical findings, and symptoms are used. Since we were interested in the
divergence between subjective symptoms and demonstrable objective disease, we did not
want to confound the assessment of disease severity with symptom reports. We therefore
used erythrocyte sedimentation rate (ESR) 28,29and standardized physician ratings of joint
swelling to index disease severity and activity. ESR was chosen because of its demonstrated
superior sensitivity 30, and was determined using the Westergren method.
Joint swelling is an index of overall disease activity 31. It was rated on a four point scale
with a standardized, 28-joint physical examination 32–34 by a rheumatologist who was blind
to the patient’s treatment status. This method yields reproducible results which are
associated with ESR results and immunological measures 32–34. Joint tenderness was also
rated, but was not included in these analyses because it is confounded by the patient’s
subjective self-report and is not therefore a pure measure of objective disease severity 28.
Grip strength was tested with a hydraulic hand dynamometer. Three readings were obtained
for each hand and then averaged 35,36. Walking time was tested by asking the patient to walk
65 feet at his/her “usual pace,” and timing this with a stop watch 37,38.
Medications—The patient’s current arthritis medication regimen was obtained at each
assessment. Medications were then grouped into analgesics, non-steroidal anti-inflammatory
agents, COX-2 inhibitors, disease-modifying anti-rheumatic drugs (DMARDs), biological
response modifiers, steroids, and antidepressants prescribed for pain. These were then
arrayed hierarchically into 4 classes according to the aggressiveness of treatment and degree
of associated risk: symptomatic drugs, steroids, DMARDS, and biological response
modifiers.
Psychological Distress—Depression is prevalent in RA and has a major influence on
pain and role impairment and disability 39–41. We assessed psychological symptoms using
the Rand Mental Health Inventory (MHI), a self-report inventory of common psychological
symptoms, that has a high degree of internal consistency and external validity 42–45. It does
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not include physical or psychosomatic symptoms. We employed the 18-item version,
containing anxiety and depression subscales.
Statistical Methods
The a priori specified primary outcome measure was the change in the RASQ score at 12
months. Using an intention to treat strategy, patients who did not complete the RASQ at 12
months had their last observations carried forward. To insure balance, the following
covariates were chosen before analysis: therapist, age, gender, white versus non-white,
married versus not, education, time since RA diagnosis, medication use, number of swollen
joints, and sedimentation rate. All of these covariates, plus the baseline RASQ score, were
included in a linear regression with the change in total RASQ score as the outcome and the
3-group treatment variable as the primary predictor. If the 3-group F-test for treatment was
significant at p<.05, then pairwise tests were carried out with a Bonferroni-adjusted p-value
of 0.025. The robustness of the conclusions was investigated by repeating the analyses
without covariate adjustment, and by analyzing only the subset of patients who completed
the 12-month follow-up assessment.
Seven secondary outcomes were analyzed in the same way: RASQ pain scores; MHI
depression and anxiety scores; and AIMS mobility, household chores, self care, and social
activities scores. Two additional outcomes, walk time and grip strength, were also analyzed
to examine objective measures of physical functioning that we did not expect to benefit from
treatment.
Secondary analyses were carried out to examine treatment effects immediately after
treatment and 6-months later, as well as to examine symptom progression over time. A
repeated measures linear regression model was constructed using the MIXED procedure,
allowing an unstructured correlation matrix to account for dependence in the serial follow-
up measures. All repeated measures models included the covariates listed above for the 12-
month analyses, and time was included as a 4-category predictor. The initial model included
interaction terms between treatment and time and a partial F-test was used to decide whether
treatment differences occurred at any time during follow-up. If the test of interaction was
non-significant, the interaction terms were removed from the model and the effect of time
was assessed using a partial F-test. The last-observation-carried-forward strategy was used.
Effect sizes were calculated to depict changes in outcome over time. Mean changes were
adjusted for the covariates listed above through linear regression models with change-from-
baseline as the outcome variable. The adjusted mean changes were then standardized by
dividing by the standard deviation at baseline.
RESULTS
Figure 1 presents the flow of patients through the study. Of the 1680 patients initially
screened for eligibility, 168 were enrolled and randomized to one of the three treatment
arms.
The 3 treatment groups are compared at baseline in Table 1, where it can be seen that the
study population is predominately female, Caucasian, and middle-aged. Their arthritis is
chronic, having been present for approximately 13 years. The three groups did not differ
significantly at baseline.
Longitudinal Change
Table 2 presents the 12-month treatment outcomes. Pain improved significantly with RR and
AE and showed a non-significant positive trend with CBT. Overall symptoms (total RASQ)
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were significantly improved with AE and CBT, and showed a non-significant positive trend
with RR. Despite a few isolated instances of improved role functioning, there was no overall
benefit. Nor did depression or anxiety improve with any of the treatments. As Table 2 also
shows, there were no significant or meaningful differences across the three treatment arms.
Table 3 shows the time course of treatment effects. For all of the outcomes, the time-by-
treatment interaction p-values are non-significant, indicating that changes in outcome over
time were similar across the 3 arms, supporting our prior conclusion that there were no
differences across treatment groups. There were no significant differences in the arthritis
medication regimens of the three treatment groups. Thus the mean number of medications
per patient at baseline and follow-up did not differ across the three treatment arms. Nor did
the proportion of patients taking DMARDs or biologic response modifiers differ
significantly at baseline or follow-up across the three treatment arms.
When the results are aggregated across treatment groups, there were significant
improvements from baseline through follow-up in four of our outcomes. Table 3 indicates
significant improvements in the total RASQ scores (p<.001), in the RASQ pain scores (p<.
001), in the AIMS self-care scores (p=.02), and the AIMS social activities scores (p=.01)1.
Finally, walk times actually worsened significantly over time (p=.01) and grip strength did
not change over time.
These improvements over time, and their consistency across treatment groups, is shown
more clearly in Figure 2. Effect sizes are displayed for outcome variables with significant
changes over time (RASQ pain, RASQ total symptoms, and AIMS social activities), as well
as for one non-significant outcome (AIMS household chores) for comparison. The effect
sizes for pain and for total symptoms displayed in Figure 2a range between 0.26 and 0.35 for
post-treatment. They are significant for all treatment groups. These are maintained at 6
month follow-up for all symptoms and treatment groups except the total score in the RR
group. At 12 month follow-up all effect sizes remained positive in the small to medium
range 46. However pain and total symptoms in the CBT group and pain in the RR group
failed to reach significance. The psychosocial outcome variables show a more
heterogeneous picture at post-treatment (see Figure 2b). At 6 month follow-up all groups
show positive improvements on the AIMS social activities and household chores scales.
Significant positive treatment effects result only for AIMS social activities at 12 month
follow-up in the CBT and the RR treatment arms with effect sizes of 0.21 and 0.37
respectively.
Efficacy Results
A substantial number of patients did not attend all treatment sessions. Significantly fewer of
the patients randomized to CBT, 57%, completed at least 8 of the 12 therapy sessions, while
80% and 83% of patients randomized to relaxation response or arthritis education,
respectively, completed at least 6 of their prescribed 8 sessions. In order to understand
whether the negative findings in the intent-to-treat analyses could have been due to the
disproportionately large number of CBT patients who did not complete their treatment, we
carried out a secondary completers analysis of the 114 patients who attended at least 80% of
their treatment sessions. There were no significant differences across treatment arms for any
of our 10 outcome measures. Completers had significantly more improvement in anxiety
(p=.01) and AIMS mobility (p=.046) than did non-completers.
1Since depression and anxiety scores were only measured at baseline and 12 months, data were already shown in Table 2 and although
further adjusted analyses suggested improvement over time, this did not reach statistical significance [depression = .35 point
improvement (se=.23), p=.12; anxiety = .15 point improvement (se=.23), p=.52].
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We found that three psychosocial treatments targeting rheumatoid arthritis symptoms were
statistically and clinically beneficial, with treatment effect sizes in the small to moderate
range. Our primary hypothesis was not supported, as there were no significant differences in
treatment outcome across the three treatment modalities. These effects were apparent
immediately following treatment and were generally sustained 6 and 12 months later, though
slightly attenuated. The treatment was beneficial for pain and other arthritis symptoms, and
for social and self-care ability, but not for mobility or the performance of household chores,
or for depression or anxiety or physical function. Because depression and anxiety did not
improve, this suggests that they did not mediate the treatment effect, i.e., that somatic
symptom improvement did not result from a lessening of psychological distress.
These findings are compatible with the existing literature, which indicates that modest but
meaningful benefits, on the order of those achieved with symptomatic RA treatments such
as NSAIDs, can be achieved over and above standard medical therapy. However, we did not
find a treatment effect on anxiety or depression, which some other studies have reported. For
example, recent studies have found that cognitive behavior therapy and mindfulness
meditation both produce significant improvements not only in pain and well-being, but also
on psychological distress and coping 9,47. Astin et al 11 analyzed 25 randomized, controlled
trials of psychosocial treatments for rheumatoid arthritis. The mean follow-up interval was
8.6 months. The pooled treatment effect size for pain immediately after treatment was 0.22
(p=.003) but at follow-up it was 0.06 (p= ns); the pooled treatment effect size for functional
disability post-treatment was 0.27 (p=.001), but at follow-up it was 0.12, again not
significant. Thus the benefits of treatment for pain and disability were found to attenuate
over time. These treatment effects were over and above the benefits of standard
rheumatological care.
Dixon et al 10, in a more recent meta-analysis of 27 studies, examined only the effects
immediately following treatment. They found a mean post-treatment effect size of 0.18 (p
<. .01) for pain, 0.20 (p < .01) for depression, 0.28 (p < .01) for anxiety, and 0.15 (p < .01)
for physical function. No statistically significant post-treatment benefit was seen for
symptoms other than pain, such as stiffness and fatigue. The authors noted that these effect
sizes approximated those seen with non-steroidal anti-inflammatory agents. In a meta-
analysis of patient education interventions, Superio-Cabuslay 12found the weighted average
effect size for pain was 0.17 and for functional disability was 0.18. The average effect size
for tender joints was .028. The median duration of these trials was 4 months. As noted
above, these represent the additional effects of education beyond those achieved with
standard medical care.
In the current study, the treatment effect did not differ significantly across the three
modalities. Arthritis education (AE), which was originally intended as an “attention control”
treatment, provided the non-specific therapeutic elements of encouragement, positive
expectations, an enhanced sense of efficacy, and social support (indeed, several of the AE
groups continued communicating and meeting with each other after the study ended). AE
did not however include any of the more specific, active ingredients of the other two
treatments, and there was no problem solving or skills training. However, a substantial
literature indicates that education and information alone do provide statistically significant
and clinically meaningful benefit 48–52.
A true no-treatment control group was not included in our study design because patient
education is now an accepted part of optimal RA treatment. Design considerations also
pushed us toward a potent “attention control” since such treatments must be interesting and
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substantive enough to retain the participants, thereby avoiding differential attrition.
However, the absence of a true no treatment control group makes it difficult to determine
whether all three treatments were equally effective or equally ineffective. Several lines of
reasoning suggest the former. First, the literature contains many studies with no treatment
control groups in patient populations similar to ours, and no significant improvement was
found in RA symptoms, impairment, or psychological distress over follow-up intervals up to
1 year 15,20,53–61. Second, none of our treatment groups improved in disease severity at any
of the time points, so the symptom improvement cannot be attributed to improved RA.
Third, the effect sizes we observed for all three treatments are comparable to those reported
with other active psychosocial treatments for rheumatoid arthritis pain, which tend to be
between .25 and .40 10–12. Finally, the time course of our treatment effect is unlikely to
result from a regression to the mean where one would expect gradual, progressive
improvement over time rather than the immediate decline in symptoms followed by a
constant, stable level of symptoms over time, as occurred in our study.
The study has a number of limitations. First, the sociodemographic and clinical
characteristics of our sample limit generalization. Most patients were in ongoing care at an
academic medical center and as such may not be representative of the reference population.
Second, the medication regimens were only ascertained at the follow-up points and not
continuously in between. Third, we did not obtain x-ray evidence of disease severity or
additional inflammatory markers of disease activity such as cytokine levels. Finally, because
of sampling variability, it is possible that CBT had a beneficial effect that we were unable to
detect. However, based on 95% confidence intervals for our 12-month comparisons, it is
very unlikely that CBT could be superior to patient education by more than 0.67 points on
the RASQ pain scale (a standardized change of 0.26 sd), nor more than 0.42 points on the
RASQ total symptom score (a standardized change of 0.23 sd). Performing an additional
study to rule-out such a small advantage of CBT over patient education would require a
sample size of approximately 300 patients per arm.
Although these treatment benefits are modest, they were achieved over and above optimal
medical therapy. Thus they constitute an effective augmentation to standard medical
therapy, achieved in a chronically ill population who had been sick for over 12 years; it is
possible that the benefit might be greater in patients with early disease since there is likely to
be greater flexibility and latitude for behavior and cognitive change early in the course of
illness when coping styles have not yet become rigidified and less adaptable. Finally, the
fact that all three treatments were comparable suggests that the less expensive, complex, and
time-consuming psychosocial treatments may be the preferable adjunct to standard
rheumatological care.
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Flow Chart for patient recruitment and follow-up
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Figure 2a Treatment gains over time for arthritis pain and arthritis total symptoms.
Standardized effect sizes are displayed with 95% confidence intervals for changes from
baseline to post-treatment, 6-months and 12-months.
Figure 2b Treatment gains over time for social activities and household chores.
Standardized effect sizes for changes in social activities and household chores from baseline
to 6-months and 12-months.
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Table 1
Baseline Characteristics: demographics, disease severity, and medication
Treatment Arms
Characteristic CBT RR AE pa
Sample size n = 68 n = 44 n = 56
Age in years (M + SD) 54.3 (13.1) 54.0 (12.3) 51.9 (13.4) .59
Years since diagnosis (M + SD) 12.4 (11.3) 13.9 (10.2) 14.1 (13.1) .54
Gender (% female) 90 82 87 .48
Race (%) .66
      white 85 75 77
      black 9 14 16
      other 6 11 7
Education (%) .63
      high school 21 11 11
      some college 19 25 18
      college 26 18 29
      graduate school 34 45 43
Martial status (%) .85
      married 51 48 46
      single 19 23 25
      widowed/divorced 30 29 29
Receiving disability (%) 29 23 23 .68
Currently employed (%) 50 57 64 .28
Disease severity (M+SD)
      Swollen joints 3.3 (4.0) 5.0 (6.0) 4.0 (3.6) .22
      Erythrocyte sedimentation rate 23.2 (16.2) 23.4 (21.1) 28.1 (19.5) .23
      Walk time 14.6 (3.9) 16.3 (6.9) 16.1 (5.1) .11
      Grip Strength dominant hand 33.0 (21.4) 34.1 (20.6) 29.9 (19.4) .55
      Grip Strength non-dominant hand 32.0 (20.6) 30.8 (20.3) 26.0 (20.3) .16
Medications (%)
      Symptomatic drugs 75 91 77 .09
      Steroids 29 34 23 .48
      Disease-modifying anti-rheumatic drugs 63 59 57 .78
      Biologic response modifiers 44 36 50 .39
      Total medications (M+SD) 2.7 (1.5) 2.6 (1.3) 2.5 (1.2) .78
Note. Patient characteristics for each study arm are described using means and standard deviations for continuous measures and percentages for
categorical measures. CBT = Cognitive behavioral therapy; RR = Relaxation response training; AE = Arthritis Education.
a
P-values for the comparisons of the three groups are from Fisher exact tests for categorical variables and the rank-based Kruskal-Wallis test for
continuous measures.
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Table 2







changeOutcome Measure Mean (SE) Mean (SE) Meana,b (SE)
RASQ Pain (VAS: 1–10)
      CBT 3.8 (.31) 3.2 (.31) − .51 (.30) .09
      RR 4.0 (.37) 3.2 (.39) − .92 (.39) .02
      AE 4.0 (.37) 3.1 (.34) − .74 (.34) .03
      Between Groups p-valuea .70
RASQ Total Symptoms (VAS: 1–10)
      CBT 2.8 (.21) 2.4 (.21) −.40 (.21) .053
      RR 3.3 (.31) 2.8 (.32) − .46 (.27) .09
      AE 3.1 (.25) 2.4 (.25) −.61 (.24) .01
      Between Groups p-valuea .81
AIMS Mobility (1–5)
      CBT 1.6 (.24) 1.7 (.26) + .23 (.20) .27
      RR 1.4 (.28) 1.0 (.22) − .51 (.27) .06
      AE 1.5 (.28) 1.3 (.23) − .11 (.23) .65
      Between Groups p-valuea .09
AIMS Household Chores (1–5)
      CBT 1.5 (.32) 1.4 (.30) + .11 (.22) .63
      RR 0.9 (.22) 0.8 (.20) − .47 (.29) .11
      AE 1.6 (.29) 1.2 (.22) − .29 (.26) .26
      Between Groups p-valuea .24
AIMS Self Care (1–5)
      CBT .46 (.17) .51 (.21) + .04 (.17) .81
      RR .28 (.10) .21 (.09) −.51 (.22) .03
      AE .99 (.26) .46 (.14) −.20 (.20) .32
      Between Groups p-valuea .16
AIMS Social Activities (1–5)
      CBT 4.5 (.21) 4.2 (.19) −.38 (.18) .03
      RR 4.5 (.29) 4.0 (.27) −.67 (.23) .005
      AE 4.9 (.24) 5.0 (.24) + .22 (.20) .28
      Between Groups p-valuea .02
MHI Depression (0–20)
      CBT 5.1 (.47) 4.8 (.47) −.29 (.36) .42
      RR 4.8 (.54) 4.5 (.60) −.48 (.47) .31
      AE 4.8 (.51) 4.3 (.55) −.32 (.41) .44
      Between Groups p-valuea .95




















changeOutcome Measure Mean (SE) Mean (SE) Meana,b (SE)
MHI Anxiety (0–20)
      CBT 6.2 (.49) 6.1 (.46) −.26 (.35) .46
      RR 6.1 (.65) 6.1 (.62) − .05 (.46) .92
      AE 5.9 (.47) 5.7 (.48) −.13 (.41) .75
      Between Groups p-valuea .93
Walk time (seconds needed for 65 feet
at usual pace)
      CBT 14.6 (.48) 15.8 (.46) + 1.0 (.40) .04
      RR 16.3 (1.0) 17.1 (1.0) + 0.6 (.61) .31
      AE 16.1 (.70) 17.9 (.86) + 2.3 (.54) p<.001
      Between Groups p-valuea .11
Grip strength, dominant hand (pounds
per square inch)
      CBT 33 (2.6) 35 (2.6) + 2.2 (1.3) .09
      RR 34 (3.1) 35 (3.4) + 0.8 (1.7) .63
      AE 30 (2.6) 31 (2.8) + 1.1 (1.5) .46
      Between Groups p-valuea .77
Note.
*
Results shown are based on last observation carried-forward for missing data.
a
Baseline and 12-Month means are unadjusted. Mean Changes and p-values are adjusted by linear regression for baseline score, therapist, age,
gender, race, marital status, education, time since RA diagnosis, symptomatic drug use, number of tender joints, number of swollen joints, and
sedimentation rate.
b
For all outcomes except grip strength, lower scores are better and negative changes at 12 months correspond to improvement.
CBT = Cognitive behavioral therapy; RR = Relaxation response training; AE = Arthritis Education; VAS = visual analog scale.
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